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In the longer term, however, midwives have to face a more
important question. Do they want their profession to be
regulated by disciplinary procedures designed primarily for
nurses? Midwives are practitioners in their own right. Doctors
are not governed by firm rules, and the General Medical
Council recognises the importance of individual judgment in
clinical matters. Though the midwives' rules should remain,
at least for the time being, the midwives' disciplinary system
should be seen to recognise how delicate the interpretation of
these rules may be. The high court, which hears appeals
against UKCC decisions, should not be the forum in which
midwives regulate themselves. A separate disciplinary system
for midwives that recognises their status as practitioners may
be the best way to avoid further damaging public disputes.
JAMES OWEN DRIFE
Senior Lecturer in Obstetrics and Gynaecology,
Leicester Royal Infirmary,
Leicester LE2 7LX
1 Hodgkinson N. Midwifery crisis as home birth lobby fights sackings. Sunday Times 1988 18 Sept;
section H: I
2 Myles MF. Textbook for midwives. 6th ed. Edinburgh: Livingstone, 1%9.
3 General Medical Council. Professional conduct and discipline:fitness to practise. London: GMC, 1983.
4 United Kingdom Central Council for Nursing, Midwifery and Health Visiting. Handbook of
midwives rules. London: UKCC, 1986.
Regular Review
Recent research on the causes of Alzheimer's disease
What causes neuronal death, and why the specific patterns?
Alzheimer's disease is now the commonest primary degenera-
tive dementia, accounting for at least half of all the cases of
dementia examined at necropsy. As the numbers of elderly
people in our population increase, moreover, it will become
one of the most frequent causes of death, affecting at least a
20th of those aged over 65 and as many as a quarter over 80.
Until 20 years ago Alzheimer's disease was regarded as one of
the inevitable consequences of aging, but recent research has
shown that this is too simple a picture.
The neuropathological changes in Alzheimer's disease
are characteristic: neuronal loss, senile plaques, and neuro-
fibrillary tangles. So it was natural to conclude that here was a
disease entity, with its own causes, natural course, and
potential specific treatment. Such a conclusion gained
impetus from the discovery of the cholinergic deficit in
Alzheimer's disease. Central cholinergic systems had already
been implicated in neuropharmacological models of memory
and so it seemed plausible that the profound memory
disturbances in Alzheimer's disease were caused by a selective
loss of cholinergic neurones.' Soon it became clear, however,
that the picture was by no means so simple. Deficits were
consistently found in other brain neuropeptides, particularly
corticotrophin releasing factor2 and somatostatin.3
The clinical features (memory deficits, poor judgment, and
deterioration in temperament and behaviour) lead gradually
and indirectly to death and so impair the demented patients
that they need full time care. These same clinical features
point to a large problem for research. We know so little about
the biological basis of higher mental functions that we cannot
distinguish which among the many known abnormalities
produce the symptoms and which initiate the disease. Here
we review the recent studies on molecular mechanisms in the
causes of Alzheimer's disease.
Genetic studies
Although only one in 1000 of the general population under
the age of 65 has Alzheimer's disease,4 about one in three
patients with the condition have a similarly affected first
degree relative-a pattern consistent with the effects of an
autosomal dominant gene.5 Nevertheless, such a finding does
not necessarily imply a genetic cause: shared environmental
factors might be responsible and in any case the incidence
might be exaggerated by selective reporting.
Studies of twins can help evaluate the genetic and environ-
mental factors. Kallman et al studied 108 pairs of twins in
whom each index twin had senile dementia (in most cases
diseases like Alzheimer's), finding that monozygotic twins
had a rate of concordance of 43%, dizygotic twins 81%,
siblings 7%, and parents 3%.6 Hence, though genetic factors
are an important causal factor, others also play an appreciable
part-a point emphasised in other studies.7
Another genetic angle has come from neuropathological
studies of middle aged patients dying with Down's syndrome
who show changes indistinguishable from Alzheimer's dis-
ease.' The inference often drawn is that excess genetic
material on chromosome 21 may cause Alzheimer's disease.
This has stimulated much research for a specific gene on
chromosome 21 coding for a protein associated with abnormal
aging or neuronal death, in which cerebral amyloidogenic
proteins have provided a starting point. Intracellular amyloid
consists mostly of neurofibrillary tangles made up of paired
helical filaments. Extracellular amyloid is the main protein
component of amyloid filaments deposited as plaques among
degenerating neurones near the cerebral vessels.910 Vascular
amyloid is now known to be part of a much larger precursor,
possibly a membrane structure, with its gene on chromosome
21."' Early in 1987 the pedigrees of four families were
described in which Alzheimer's disease seemed to be
an autosomal dominant, the genetic defect also being on
chromosome 21.12 Soon it was being suggested that the
"familial Alzheimer gene" and the amyloid protein gene were
identical."3 Further studies showed, however, that these
claims could not be supported: in familial Alzheimer's disease
the disorder does not segregate exclusively with the amyloid
protein gene and this gene is not present in excess in either
sporadic Alzheimer's disease or Down's syndrome.'4"1It is
now clear that the gene for the amyloid protein is not the gene
for familial Alzheimer's disease and is not the cause of
Alzheimer's disease. 16 Nevertheless, abnormalities in the
control of the synthesis of cerebral amyloidogenic proteins
may still be shown to contribute to Alzheimer's disease.
More immediately relevant is the application of these
genetic observations to the threshold model of Alzheimer's
disease.'7 In the familial condition the genetic contribution
would be less than in Down's syndrome and the contribution
of factors related to age would be greater. In so called
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"sporadic" cases the contribution of aging would be more
important than genetic factors.'8
In Down's syndrome, Alzheimer's disease, and several
genetically determined conditions with chronic neurological
sequelae there is an impaired ability to repair DNA damage
induced by a wide range of agents,'9 and the neurones might
be particularly affected. A further topic for research has
concerned nerve growth factor, a protein present at the
terminals of cholinergic neurones in the basal nuclei that
affects their function.20 Rats with experimentally induced
lesions resembling those in Alzheimer's disease had the
degenerative process alleviated after treatment with nerve
growth factor. Intraventricular injections of nerve growth
factor improved the performance of aged rats in a spatial
memory task.2' Hence a defect in the synthesis or action of
nerve growth factor might contribute to the loss of neurones
concerned with memory that occurs in Alzheimer's disease.
These and other lines of evidence suggest that there are
potentially multiple defects in Down's syndrome leading to
the neuropathological changes in Alzheimer's disease: (a) an
accumulation ofa toxic metabolic product ofan enzyme coded
on chromosome 21; (b) synthesis of excess receptors that
exaggerate the effects of a neurotoxin; (c) severely restricted
adaptive capacity, related to malformation of the brain22; (d)
impaired capacity to repair damage to DNA caused by an
endotoxin; and (e) absence of a neurotrophic factor.23
Infective agents
Studies on scrapie, a neurodegenerative disease of sheep,
provided the first clue for a role for infection in Alzheimer's
disease. Unlike other infective agents, scrapie causes no fever
or inflammatory or immune responses. When inoculated
into mice scrapie produces neuropathological changes that
include neuritic plaques and a reduced activity of cholinergic
synthetic enzymes.24 Scrapie may be caused by an infectious
pathogen known as a prion, a protein without detectable
nucleic acids. An original proposal was that the similar
staining reactions of aggregates of prions and plaques indi-
cated that they might be identical.25 Later studies suggested,
however, that the amyloid proteins of both the blood vessels
and the plaques are distinct from that of prions.26 But do
prions cause scrapie or are they part of the cellular response
derived by the host to another, unknown, causal agent?
A gene coding for prion protein has now been located in the
human genome on chromosome 20,2728 not, as predicted by
the Down's model ofAlzheimer's disease, on chromosome 21.
Possibly this protein might be concerned in the pathogenesis
of Alzheimer's disease, arising either from a process initiated
by a pathogen or as part of the pathogen itself. Against this
theory, however, is the failure to transmit Alzheimer's disease
to animals, which is strong evidence against the role of an
infectious agent.29
Metabolism and toxins
Much evidence points to a defect in intraneuronal transport
in Alzf eimer's disease. Proteins associated with the micro-
tubules forming the framework of the neurones can be
detected in the characteristic tangles,30 and one of the proteins
(tau) may be an important constituent of the paired helical
filament.3 32 Moreover, assembly of microtubules is disrupted
in Alzheimer's disease. A critical concentration of tubulin is
necessary for this process, and its concentration is low
in postmortem specimens of temporal cortex taken from
patients with Alzheimer's disease.33 Preparations from normal
brains taken two to four hours after death can form micro-
tubules whereas those from patients with Alzheimer's disease
cannot, although both can form neurofilaments.3 Moreover,
specimens from the diseased brains have no abnormality in
tubulin and no microtubule inhibitor and their tau protein is
abnormally phosphorylated. When DEAE dextran (which
mimics the effect of tau protein) was added it induced the
formation of microtubules. Finally, preliminary reports
indicate that protein A68, a phosphokinase for tau protein, is
greatly increased or exclusively present in the brain and the
spinal fluid of patients with Alzheimer's disease.35 Thus
abnormal phosphorylation of tau protein may be a key step in
the formation of neurofibrillary tangles, although the origin of
the abnormality remains obscure.
Tau protein antigens have been shown in the intracellular
inclusions of Pick's disease and progressive supranuclear
palsy, which suggests that a tau protein abnormality may be
found in other conditions36 and that the abnormality may be
only one of several factors that lead to cellular disruption.
Apart from mechanical disruption and cytoskeletal ab-
normalities, the neurones of patients with Alzheimer's disease
might be vulnerable to peroxidation by free radicals. Damag-
ing free radicals are metabolised within the cells by the
enzyme superoxide dismutase. The enzyme produces
peroxide, an oxidant, which is rendered harmless in the brain
by the enzyme glutathione peroxidase. The gene for super-
oxide dismutase is located on chromosome 21, and in trisomy
21 (Down's syndrome) its activity is increased by a half,
leading to an excess of peroxide. In patients with Down's
syndrome there is a significant correlation between intelli-
gence and glutathione peroxidase activities.37 In patients with
Alzheimer's disease the activity of the superoxide dismutase
in the brain is no different from that in controls, whereas the
activity of glutathione peroxidase is raised, which suggests
that the neurones may suffer increased oxidative damage.38 39
The increased activities of glucose 6-phosphate dehydro-
genase and glucose 6-phosphogluconate dehydrogenase that
are found in Alzheimer's disease may be due to increased
metabolism of brain peroxide.'
The successful disposal of free radicals results in
membranes retaining their fluidity and a reduced accumula-
tion of intracellular pigment. Oxidative damage can be
measured by decreased fluidity of platelet membranes and
occurs in normal aging as well as in patients with Down's
syndrome.4' Contrary to expectations, however, in patients
with Alzheimer's disease the fluidity of platelet membranes is
increased, and this may correlate with the severity of the
dementia.42 Hence Alzheimer's disease does not just represent
accelerated aging and the cause of increased fluidity of
membranes is not known.
Processing of information is carried out most effectively by
neurones that have efficient oxidative processes. These
processes are depressed both by aging and by Alzheimer's
disease.43 With positron emission tomography a high correla-
tion can be shown between intelligence scores and the rate of
metabolism of glucose in both patients with Alzheimer's
disease and normal controls4'; in the patients, however,
cerebral metabolism of glucose is both decreased and different
between the right and left cerebral hemispheres.45
Does a toxic or deficiency state lead to Alzheimer's
disease?
Aluminium, the most abundant metal on the earth's crust,
is an important toxic agent in dialysis dementia, though this
differs clinically from the dementia in Alzheimer's disease.
Neurofibrillary tangles composed of 10 nm filaments can
be induced in animals by the intracerebral injection of
aluminium salts,-* but these are different from the tangles in
Alzheimer's disease.4748 Reports of the accumulation of alu-
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minium in the brains of patients with Alzheimer's disease49 50
have not always been confirmed.5'
Possibly, however, aluminium may play an indirect part by
altering the metabolism of minerals. Three geographically
distinct populations show a considerable increase in the
incidence of a neurodegenerative complex: the Chamorros of
the island of Guam in the Mariane islands; the Auyu and the
Jolu people of western New Guinea; and the Japanese of the
Hobara and Kozagarra districts of the Kii peninsula of
Honshu island. Neuropathologically the patients have the
features of motor neurone disease, Parkinson's disease, or
Alzheimer's disease, or combinations of these. It has been
postulated that the incidence ofthis complex of diseases varies
with local geology52; Guam, the Kii peninsula, and western
New Guinea share low concentrations of calcium and mag-
nesium in the soil.and drinking water and high concentrations
of aluminium and iron."
Clinical studies of patients of the Chamorros people have
shown abnormalities in the metabolism of calcium and
vitamin D and their brains at necropsy have shown intra-
neuronal deposition of both calcium and aluminium.5455 A
recent review has concluded that there is considerable support
for the hypothesis of a defect in mineral metabolism in these
neurodegenerative disorders,56 which have declined with the
introduction of calcium and magnesium to the areas. The
areas have also become increasingly Westernised and the local
diet has moved away from dependence on flour made from
the cyad nut. This and other evidence has led to recent
suggestions of an alternative hypothesis: a nutritional change
has reduced the incidence of the disorders, which may have
been caused by "free excitatory" neurotoxic amino acids such
as 13-N-methylamino-L-alanine.57 58 Migrants from these areas
have developed the disorders years later, suggesting that an
environmental insult interacts with the aging process leading
to the disorder once a threshold has been passed.
If environmental causes are responsible for the complex of
parkinsonism-dementia of Guam then they may contribute to
the similar neurofibrillary tangles of Alzheimer's disease.
Aluminium and silicon are found in the cores of senile
plaques,59 and x ray microanalysis has shown calcium and
aluminium together in the affected neurones from patients
with parkinsonism-dementia of Guam." This deposition may
lead to impaired axonal transport and facilitate the formation
of neurofibrillary tangles. But is this indeed the sequence of
events? Aluminium and silicon deposition might follow the
abnormal accumulation of cytoskeletal elements found in the
neurofibrillary tangles and plaques.6' Dystrophic mineralisa-
tion such as that found in Alzheimer's disease and the
parkinsonism-dementia of Guam may also follow abnormal
calcium metabolism, and there is some evidence for dis-
ordered calcium metabolism in Alzheimer's disease. Calcium
homeostasis is altered by aging but more so by Alzheimer's
disease.43 Increased concentrations of bound cell calcium are
found in the skin fibroblasts in Alzheimer's disease when
patients are compared with controls. Other alterations in
calcium metabolism in the nervous system suggest that these
may have a role in Alzheimer's disease.62-65
Conclusions
All the evidence we have discussed does not provide
temporal sequence ofthe pathogenesis ofAlzheimer's disease.
In broad terms, however, there are two possibilities. Firstly,
Alzheimer's disease may be a single disease process with a
fixed sequence of pathological changes. Each of the abnor-
malities described above would then represent a necessary
link in such a causal chain, leading to the death of specific
populations of cells. Secondly, like motor neurone disease,
Alzheimer's disease may be the end point of many distinct
pathways, each of which can lead to neuronal death. Some
patients will develop Alzheimer's disease in a manner akin to
Down's syndrome so that genes from chromosome 21 are
sufficient to produce all the neuropathological changes and
clinical features. Other patients may cross a threshold for the
disease only after an initiating event such as a head injury'1 or
exposure to a neurotoxin.67
Peroxides (aging,
poor scavenging
of free radicals)
Vulnerability
of specif ic
brain areas
Some suggested relations among possible causal factors (given in parentheses) in
Alzheimer's disease, the selective loss of neurones, and the principal symptoms of the
disorder
Whatever the eventual answer, two main themes emerge
from the results of research. Firstly, there is considerable
support for the notion that neuronal integrity may be
compromised in Alzheimer's disease by both intracellular
disruption and abnormal fluidity of membranes. Secondly,
there is little to indicate why there is a specific pattern of cell
death, but the circumscribed distributions of certain proteins
in the brain (for instance, calmodulin) are possible starting
points for further research. Above all we must answer the two
key questions (figure): Why do neurones die? And why do
they die in specific patterns leading to characteristic clinical
syndromes?
I J DEARY
Lecturer in Psychology,
University of Edinburgh,
Edinburgh EH8 9JZ
L J WHALLEY
Senior Lecturer in Psychiatry,
Royal Edinburgh Hospital,
Edinburgh EH1O 5HF
BMJ VOLUME 297 1 OCTOBER 1988
Neurofibrillary tangles (abnormal
phosphorylation of tau protein,
? aging)
Lipofuscin (aging, poor scavenging
of free radicals)
Mineral deposits (altered mineral
metabolism)
809
1 Coyle JT, Price DL, De Long MR. Alzheimer's disease: a disorder of cortical cholinergic
innervation. Science 1983;219:1184-90.
2 De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW. Reciprocal changes in
corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex
of Alzheimer's disease. Nature 1986;319:593-5.
3 Davis P, Katzman R, Terry RD. Reduced somatostatin-like immunoreactivity in cerebral cortex
from cases of Alzheimer disease and Alzheimer senile dementia. Nature 1980;288:279-80.
4 Whalley LJ, Carothers AD, Collyer S, de Mey R, Frackiewicz A. A study of familial factors in
Alzheimer's Disease. BrJ Psychiatry 1982;140:249-56.
5 Heston LL, Mastri AR, Anderson VE, White J. Dementia of the Alzheimer type. Clinical genetics,
natural history and associated conditions. Arch Gen Psychiany 1981;38:1085-90.
6 Kailman FJ, Feingold L, Bondy E. Comparative adaptation, social and psychometric data of the
life histories of senescent twin pairs. AmJ Hum Genet 1951;3:65-73.
7 Nee LE, Eldridge R, Sunderland T, et al. Dementia of the Alzheimer type; clinical and family study
of 22 twin pairs. Neurology 1987;37:359-63.
8 Oliver C, Holland CJ. Down's Syndrome and Alzheimner's disease: a review. Psychol Med
1986;16:307-22.
9 Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a usique
cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984;122:1131-5.
10 Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid
plaque core protein in Alzheimer's disease and Down's syndrome. Proc Natl Acad Sci USA
1985;82:4245-49.
11 Goldgaber D, Lepman MI, McBride OW, Saffiotti U, Gaidusek DC. Characterisation and
chromosomal localisation of a cDNA encoding brain amyloid of Alzheimer's disease. Science
1987;235:877-80.
12 St George-Hyslop PH, Tanzi RE, Polinsky RJ, et al. The genetic defect causing familial
Alzheimer's disease maps on chromosome 21. Science 1987;235:885-90.
13 Delabar JM, Goldgaber G, Lamour Y, et al. Beta-amyloid gene duplication in Alzheimer's disease
and karyotypically normal Down's syndrome. Science 1987;235:1390-1.
14 Tanzi RE, Bird ED, Latt SA, Neve RL. The amyloid beta protein gene is not duplicated in brains
from patients with Alzheimer's disease. Science 1987;238:666-9.
15 Podlisny MB, Lee G, Selkoe DJ. Gene dosage of the amyloid beta precursor protein in Alzheimer's
disease. Science 1987;238:669-71.
16 Van Broeckhoven C, Genthe A, Vandenberghe A, et al. Failure of familial Alzheimer's disease to
segregate with the A4 amyloid gene in several European families. Nature 1987;329:151-3.
17 Caine DB, Eisen A, McGeer E, Spencer P. Alzheimer's disease, Parkinson's disease and
motoneurone disease: abiotrophic interaction between ageing and environment? Lancet 1986;ii:
1067-70.
18 Whalley LJ, Wright AF, St Clair DM. Genetic factors in Down's syndrome and their possible role
in the pathogenesis of Alzheimer's disease. Interdisciplinary Topics in Gerontology 1985;19:18-31.
19 Wright AF, Whalley LJ. Genetics, ageing and dementia. BrJ7 Psychiatry 1984;145:20-38.
20 Hefti F, Weiner WJ. Nerve growth factor and Alzheimer's disease. Ann Neurol 1986;20:275-81.
21 Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon C, Gage FH. Amelioration of
cholinergic neuron atrophy and spatial memory impairment in aged rats with nerve growth
factor. Nature 1987;329:65-8.
22 Lund RD. Development and plasticity ofthe brain. Oxford: Oxford University Press, 1987:178-99.
23 Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, Parkinsonism and
Alzheimer's disease. Ann Neurol 1981;10:499-505.
24 McDermott JR, Fraser H, Dickinson AG. Reduced choline acetyl transferase activity in scrapie
mouse brain. Lancet 1978;ii:318-9.
25 Prusiner SB. Some speculations about prions, amyloid and Alzheimer's disease. N Engl J Med
1984;310:661-3.
26 Prusiner SB. Prions and neurodegenerative diseases. N EnglJ Med 1987;317:1571-8 1.
27 Liao Y-C J, Roger V, Lebo GA, Clawson EA. Smucklex-Human Prion Protein cDNA: molecular
cloning, chromosomal mapping, and biological implications. Science 1986;233:364-7.
28 Robakis NK, Devine-Gage EA, Jenkins EC, et al. Localization of a human gene homologous to the
P.P. gene on the arm of chromosome 20 and detection of P.P-related antigens in normal human
brain. Biochem Biophys Res Comm 1986;140:758-65.
29 Goudsmit J, Morrow CH, Asher DM, et al. Evidence for and against the transmissibility of
Alzheimer's disease. Neurology 1980;30:945-50.
30 Kosik KS, Duffy LK, Dowling MM, Abraham C, McCluskey A, Selkoe DJ. Microtubule
associated protein 2: monoclonal antibodies demonstrate the selective incorporation of certain
epitopes into Alzheimer neurofibrillary tangles. Proc Natl Acad Sci USA 1984;81:7941-5.
31 Iqbal K, Grundke-Iqbal I, Wisniewsky HM. Alzheimner's disease, microtubule and neurofilament
proteins and axoplasmic flow. Lancet 1987;i:102.
32 Grundke-Iqbal I, Iqbal K, Tung Y-C, et al. Abnormal phosphorylation of the microtubule
associated protein (tau) in Alzheimer cytoskeletal pathology. Proc Natil Acad Sci USA
1986;83:44913-7.
33 Borthwick NM, Yates CM, Gordon A. Reduced proteins in temporal cortex in Alzheimer's disease:
an electrophoretic study. J Neurochem 1985;44:1426-41.
34 Iqbal K, Grundke-Iqbal I, Zaidi T, et al. Defective microtubule assembly in Alzheimer's disease.
Lancet 1986;11:421-6.
35 Ferry G. Probes for protein in Alzheimer's disease. New Scientust 1986 Dec 18:14.
36 Pollock NJ, Mirra SS, Binder LI, Hansen LA, Wood JG. Filamentous aggregates in Pick's disease,
progressive supranuclear palsy, and Alzheimer's disease share antigenic determinants with
microtubule associated protein, Tau. Lancet 1986;ii: 1211.
37 Sinet PM, Lejeune J, Jerome H. Trisomy 21 (Down's syndrome), glutathione peroxidase, hexose
monophosphate shunt and IQ. Life Sci 1979;24:29-34.
38 Marklund SL, Adolfsson R, Gottfries CG, Winblad B. Superoxide dismutase isoenzymes in normal
brains and in brains from patients with dementia ofAlzheimer type.J Neurol Sci 1985;67:319-25.
39 Anneren G, Gardner A, Lundin T. Increased glutathione peroxidase activity in erythrocytes in
patients with Alzheimer's disease/senile dementia of the Alzheimer type. Acta Neurol Scand
1986;73:586-9.
40 Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate
dehydrogenase activity in Alzheiner's disease may reflect oxidative stress. J Neurochem
1986;46: 1042-5.
41 Cohen DM, Zubenko GS. Aging and the biophysical properties of cell membranes. Life Sci
1985;37: 1403-9.
42 Zubenko GS, Cohen BM, Boiler F, Malinakova I, Keefe N, Choinacki B. Platelet membrane
abnormalities in Alzheimer's disease. Ann Neurol 1987;22:237-44.
43 Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in skin
fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci USA 1986;83:2758-62.
44 Chase TN, Fedio P, Foster NL, Brooks R, Dichiro G, Mansi L. WAIS performance: cortical
localisation by fluorodeoxyglucose F18-positron emission tomography. Arch Neurol 1984;41:
1244-7.
45 Haxby JV, Grady CL, Duara R, et al. Neurocortical metabolic abnormalities precede non-memory
cognitive deficits in early Alzheimer's type dementia. Arch Neurol 1986;43:882-5.
46 Terry R, Pena C. Experimental production of neurofibrillary degeneration. J Neuropathol Exp
Neurol 1965;24:200-10.
47 Wisniewski M, Sturman J, Shek JW. Aluminium chloride induced neurofibrillary changes in the
developing rabbit: a chronic animal model. Ann Neurol 1980;8:479-90.
48 Munoz-Garcia D, Pendlebury WW, Kessler JB, Perl DP. An immunocytochemical comparison of
cytoskeletal proteins in aluminium-induced and Alzheimer-type neurofibrillary tangles. Acta
Neuropathol (Berl) 1980;70:243-8.
49 Crapper DR, Krishnan SS, Quittkat S. Aluminium, neurofibrillary degeneration and Alzheimer's
disease. Brain 1976;99:67-80.
50 Perl D, Brody A. Alzheimer's disease: X-ray spectrometric evidence ofaluminium accumulation in
neurofibrillary tangle-bearing neurons. Science 1980;208:297-9.
51 Wisniewski HM, Moretz RC, Iqbal K. No evidence for aluminium in etiology and pathogenesis of
Alzheimer's disease. Neurobiol Aging 1986;7:532-5.
52 Kimura K. Studies on amyotrophic lateral sclerosis. I. Epidemiological, geomedical and genetic
studies on amyotrophic lateral sclerosis and its allied diseases in Ku peninsular Japan. Psychiatric
Neurologyjapan 1963;65:31-8.
53 Gajdusek D, Salazar A. Amyotrophic lateral sclerosis and Parkinsonian syndromes in high
incidence among the Auyu and Jakai people of West New Guinea. Neurology 1982;32:107-26.
54 Yanagihara R, Garruto RM, Gajausek D, et al. Calcium and Vitamin D metabolism in Guamanian
Chamorros with amyotrophic lateral sclerosis and Parkinson-dementia. Ann Neurol 1984;
15:42-8.
55 Perl DC, Gaidusek DC, Garruto RM, et al. Intraneural aluminium accumulation in amyotrophic
lateral sclerosis and Parkinson-Dementia of Guam. Science 1982;217:1053.
56 Garruto RM, Yase Y. Neurodegenerative disorders of the Western Pacific: the search for
mechanisms of pathogenesis. Trends in Neurosciences 1986;9:368-74.
57 Rowland LP. Motor neuron diseases and amyotrophic lateral sclerosis: research progress. Trends in
Neurosciences 1987;10:393-8.
58 Kurland LT. Amyotrophic lateral sclerosis and Parkinson's disease complex ofGuam linked to an
environmental neurotoxin. Trends in Neurosciences 1988;11:51-4.
59 Candy J, Oakley A, Klinowski J, et al. Aluminosilicates and senile plaque formation in
Alzheimer's disease. Lancet 1986;i:354-6.
60 Garruto RM, Yanagihara R, Gajdusek DC. Disappearance of high-incidence amyotrophic lateral
sclerosis and parkinson-dementia on Guam. Neurology 1985;35: 193-8.
61 Deary IJ, Powell K. Foetal postsynaptic densities have mineral spectra similar to those found in
amyotrophic lateral sclerosis and Parkinson-dementia of Guam. Lancet 1986;i:619-20.
62 Peterson C, Gibson GE. Aging and 3,4-diaminopyridine alter synaptosomal calcium uptake. J Biol
Chemn 1983;258:11482-6.
63 Wesseling H, Agoston S, Van Dam GBP, Pasma J, DeWitt DJ, Havinga H. Effects of
4-aminopyridine in elderly patients with Alzheimer's disease. N EngljMed 1984;310:988-9.
64 Deary IJ, Hendrickson AE, Burns A. Serum calcium levels in Alzheimer's disease: a finding and an
etiological hypothesis. Personality and Individual Differences 1987;8:75-80.
65 Gibson GE, Peterson C. Consideration of neurotransmitters and calcium metabolism in therapeutic
design. In: Crook T, Bartus R, Ferris S, Gershon S, eds. Treatment development strategies for
Alzheimer's disease. Madison: Powley, 1986:499-518.
66 Mortimer J, French L, Hutton J, Schuman L. Head injury as a risk factor for Alzheimer's disease.
Neurology 1985;35:264-7.
67 Crapper McLachlan DR. Aluminium and Alzheimer's disease. Neurobiol Aging 1986;7:525-32.
810 BMJ VOLUME 297 1 OCTOBER 1988
